Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway

American Journal of Nephrology

Volumn 35, Issue 1, 2012, Pages 90-100

  Whaley Connell, Adam T ^a,d,g   Habibi, Javad ^a,d,h   Nistala, Ravi ^a,d,g   Demarco, Vincent G ^a,e,h   Pulakat, Lakshmi ^a,d,f,h   Hayden, Melvin R ^b,d,h   Joginpally, Tejaswini ^a,c   Ferrario, Carlos M ⁱ   Parrish, Alan R ^b,e,g   Sowers, James R ^a,e,h  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Missouri   (United States)

^c Diabetes and Cardiovascular Center   (United States)

^d Departments of Internal Medicine Hepatology   (United States)

^e UNIVERSITY OF MISSOURI   (United States)

^f Nutrition and Exercise Physiology   (United States)

^g Divisions of Nephrology and Hypertension   (United States)

^h Divisions of Endocrinology and Metabolism   (United States)

ⁱ WAKE FOREST UNIVERSITY   (United States)

Author keywords

NAG; Cadherin; Megalin; Proteinuria

Indexed keywords

3 NITROTYROSINE; ALDOSTERONE; ALPHA CATENIN; CADHERIN; MAMMALIAN TARGET OF RAPAMYCIN; MEGALIN; MINERALOCORTICOID RECEPTOR; PEROXYNITRITE; PLACEBO; S6 KINASE; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DAMAGE; LOW DRUG DOSE; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION; ULTRASTRUCTURE;

ALBUMINURIA; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BLOOD PRESSURE; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULES; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; RIBOSOMAL PROTEIN S6 KINASES; SPIRONOLACTONE; TOR SERINE-THREONINE KINASES;

EID: 84455205914     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000335079     Document Type: Article

References (41)

1. Bertocchio JP, Warnock DG, Jaisser F: Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int 2011; 79: 1051-1060.
2. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58: 1219-1227.
3. Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, Stas S, Sowers JR: Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007: 293:H2009-H2023. (Pubitemid 47605846)
4. Funder JW: The non-genomic actions of aldosterone. Endocr Rev 2005; 26: 313-321.
5. Kawarazaki H, Ando K, Fujita M, Matsui H, Nagae A, Muraoka K, Kawarasaki C, Fujita T: Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats. Am J Physiol Renal Physiol 2011; 300:F1402-F1409.
6. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M: Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006; 47: 656-664. (Pubitemid 43740235)
7. Ortiz RM, Graciano ML, Mullins JJ, Mitchell KD: Aldosterone receptor antagonism alleviates proteinuria, but not malignant hypertension, in Cyp1a1-Ren2 transgenic rats. Am J Physiol Renal Physiol 2007; 293:F1584-F1591. (Pubitemid 350085995)
8. Boldyreff B, Wehling M: Aldosterone: refreshing a slow hormone by swift action. Physiology 2004; 19: 97-100.
9. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, Schiffrin EL: Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005; 45: 773-779. (Pubitemid 40418380)
10. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM: Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 2006; 20: 1546-1548.
11. Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y, Matsuoka H: Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 2006; 47: 671-679. (Pubitemid 43740237)
12. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, Kimura S, Yukimura T, Kiyomoto H, Kohno M, Abe Y, Nishiyama A: Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005; 16: 2906-2912. (Pubitemid 44743488)
13. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, Schiffrin EL, Touyz RM: Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox- sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008; 28: 1511-1518.
14. Whaley-Connell A, Habibi J, Wei Y, Gutweiler A, Jellison J, Wiedmeyer CE, Ferrario CM, Sowers JR: Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2009; 296:F1013-F1022.
15. Tabet F, Schiffrin EL, Callera GE, He Y, Yao G, Ostman A, Kappert K, Tonks NK, Touyz RM: Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. Circ Res 2008; 103: 149-158.
16. Yalcin S, Marinkovic D, Mungamuri SK, Zhang X, Tong W, Sellers R, Ghaffari S: ROSmediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3-/- mice. EMBO J 2010: 29: 4118-4131.
17. Bieri M, Oroszlan M, Zuppinger C, Mohacsi PJ: Biosynthesis and expression of VE-cadherin is regulated by the PI3K/mTOR signaling pathway. Mol Immunol 2009; 46: 866-872.
18. Chen JK, Chen J, Thomas G, Kozma SC, Harris RC: S6 kinase-1 knockout inhibits uninephrectomy- or diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 2009; 297:F585-F593.
19. Nakagawa S, Masuda S, Nishihara K, Inui K: mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats. Biochem Pharmacol 2010; 79: 67-76.
20. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W: Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 16: 2063-2072. (Pubitemid 41716437)
21. Lieberthal W, Levine JS: The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009; 20: 2493-502.
22. Jung KY, Dean D, Jiang J, Gaylor S, Griffith WH, Burghardt RC, Parrish AR: Loss of Ncadherin and α -catenin in the proximal tubules of aging male Fischer 344 rats. Mech Ageing Dev 2004; 125: 445-453. (Pubitemid 38746424)
23. Okada H, Kalluri R: Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis. Curr Mol Med 2005; 5: 467-474. (Pubitemid 41093560)
24. Parrish AR, Catania JM, Orozco J, Gandolfi AJ: Chemically induced oxidative stress disrupts the E-cadherin/catenin cell adhesion complex. Toxicol Sci 1999; 51: 80-86. (Pubitemid 29439232)
25. Chu YS, Thomas WA, Eder O, Pincet F, Perez E, Thiery JP, Dufour S: Force measurements in E-cadherin-mediated cell doublets reveal rapid adhesion strengthened by actin cytoskeleton remodeling through Rac and Cdc42. J Cell Biol 2004; 167: 1183-1194. (Pubitemid 40066632)
26. Lee JM, Dedhar S, Kalluri R, Thompson EW: The epithelial-mesenchymal transition: new insights in signalling, development, and disease. J Cell Biol 2006; 172: 973-981.
27. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S, DeFreitas G, Entman M, Carabello BA, Roberts R, Marian AJ: Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004; 109: 1284-1291. (Pubitemid 38372788)
28. Sander M, Bader M, Djavidani B, Maser- Gluth C, Vecsei P, Mullins J, Ganten D, Peters J: The role of the adrenal gland in hypertensive transgenic rat TGR(mREN2)27. Endocrinology 1992; 131: 807-814.
29. Wei Y, Whaley-Connell AT, Habibi J, Rehmer J, Rehmer N, Patel K, Hayden M, De- Marco V, Ferrario CM, Ibdah JA, Sowers JR: Mineralocorticoid receptor blockade attenuates vascular apoptosis and injury. Hypertension 2009; 53: 158-165.
30. Habibi J, Demarco VG, Ma L, Pulakat L, Rainey WE, Whaley-Connell AT, Sowers JR: Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol 2011; 300:H1484-H1491.
31. Habibi J, Hayden MR, Sowers JR, Pulakat L, Tilmon RD, Manrique C, Lastra G, Demarco VG, Whaley-Connell A: Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats. Endocrinology 2011; 152: 659-668.
32. Whaley-Connell AT, Chowdhury NA, Hayden MR, Stump CS, Habibi J, Wiedmeyer CE, Gallagher PE, Tallant EA, Cooper SA, Link CD, Ferrario C, Sowers JR: Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol 2006; 291:F1308-F1314. (Pubitemid 44887244)
33. Arnemann J, Sultani O, Hasgün D, Coerdt W: T-/H-cadherin (CDH13): a new marker for differentiating podocytes. Virchows Arch 2006; 448: 160-164. (Pubitemid 43237881)
34. Carter WB, Niu G, Ward MD, Small G, Hahn JE, Muffly BJ: Mechanisms of HER2-induced endothelial cell retraction. Ann Surg Oncol 2007; 14: 2971-2978. (Pubitemid 47460629)
35. Koller E, Ranscht B: Differential targeting of T- and N-cadherin in polarized epithelial cells. J Biol Chem 1996; 271: 30061-30067. (Pubitemid 26389645)
36. Russo LM, Sandoval RM, Campos SB, Molitoris BA, Comper WD, Brown D: Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2010; 20: 489-494.
37. Sarbassov DD, Sabatini DM: Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J Biol Chem 2005; 280: 39505-39509. (Pubitemid 41713908)
38. Xu G, Liu A, Liu X: Aldosterone induces collagen synthesis via activation of extracellular signal-regulated kinase 1 and 2 in renal proximal tubules. Nephrology 2008; 13: 694-701.
39. Whaley-Connell A, Habibi J, Panfili Z, Hayden MR, Bagree S, Nistala R, Hyder S, Krueger B, Demarco V, Pulakat L, Ferrario CM, Parrish A, Sowers JR: Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. Am J Nephrol 2011; 34: 115-125.
40. Lee JY, Chang JW, Yang WS, Kim SB, Park SK, Park JS, Lee SK: Albumin-induced epithelial-mesenchymal transition and ER stress are regulated through a common ROSc- Src kinase-mTOR pathway: effect of imatinib mesylate. Am J Physiol Renal Physiol 2011; 300:F1214-F1222.
41. Oroszlán M, Bieri M, Ligeti N, Farkas A, Meier B, Marti HP, Mohacsi P: Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin IIdependent pathway. Transpl Immunol 2010; 23: 125-132.